Selexipag for the treatment of pulmonary arterial hypertension.
Détails
ID Serval
serval:BIB_A1BB2A3A6225
Type
Article: article d'un périodique ou d'un magazine.
Sous-type
Synthèse (review): revue aussi complète que possible des connaissances sur un sujet, rédigée à partir de l'analyse exhaustive des travaux publiés.
Collection
Publications
Institution
Titre
Selexipag for the treatment of pulmonary arterial hypertension.
Périodique
Expert review of respiratory medicine
ISSN
1747-6356 (Electronic)
ISSN-L
1747-6348
Statut éditorial
Publié
Date de publication
05/2021
Peer-reviewed
Oui
Volume
15
Numéro
5
Pages
583-595
Langue
anglais
Notes
Publication types: Journal Article ; Review
Publication Status: ppublish
Publication Status: ppublish
Résumé
: Pulmonary arterial hypertension (PAH) is a rare pulmonary vasculopathy. This review focuses on selexipag, a prostacyclin receptor agonist validated for the treatment of PAH.
We review the structure, mechanisms of action, pharmacokinetics, and pharmacodynamics of selexipag. Clinical efficacy and tolerability are discussed using the main clinical trial published for selexipag (GRIPHON) and its post-hoc analysis.
Selexipag should be added as a triple oral combination therapy in case of insufficient response to oral combination therapy with endothelin receptor antagonist and phosphodiesterase 5 inhibitor. However, selexipag should not replace parenteral prostacyclin in high-risk patients.
We review the structure, mechanisms of action, pharmacokinetics, and pharmacodynamics of selexipag. Clinical efficacy and tolerability are discussed using the main clinical trial published for selexipag (GRIPHON) and its post-hoc analysis.
Selexipag should be added as a triple oral combination therapy in case of insufficient response to oral combination therapy with endothelin receptor antagonist and phosphodiesterase 5 inhibitor. However, selexipag should not replace parenteral prostacyclin in high-risk patients.
Mots-clé
Acetamides/therapeutic use, Administration, Oral, Antihypertensive Agents/therapeutic use, Humans, Pulmonary Arterial Hypertension/drug therapy, Pyrazines/therapeutic use, Endothelin receptor antagonist, guanylate cyclase stimulators, phosphodiesterase type 5 inhibitor, prostacyclin Pathway, pulmonary arterial hypertension, selexipag
Pubmed
Web of science
Création de la notice
22/01/2021 11:39
Dernière modification de la notice
09/01/2024 8:15
Données d'usage
